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THE Q RULE IN BACTERIODETES AND THE IDENTIFICATION AND 
CHARACTERIZATION OF PORPHYROMONAS GINGIVALIS GLUTAMINYL 
CYCLASE 
John Andrew Houston 
November 30th, 2018 
Background: Porphyromonas gingivalis, a major pathogen associated with chronic 
periodontitis, secretes variety of proteins, majority of which begins with glutamine. 
Several of these proteins were found with pyroglutamate (pGlu) at N-terminus 
suggesting the presence of this posttranslational modification pathway in 
P.gingivalis. The observation that N-terminal glutamine is over-represented as the 
first amino acid after signal peptide cleavage, and subsequent confirmation of pGlu 
formation on the nascent protein via mass spectrometry, led us to conclude that 
an enzyme must be present as the executor of this reaction. Hypothesis: PG2157 
is a glutaminyl cyclase and is responsible for the cyclization of N-terminal 
glutamine residues. Methods: A homology search was used to identify a gene 
(PG2157) encoding a protein homologous to human glutaminyl cyclase (QC) in the 
P. gingivalis genome.  The gene was cloned, expressed in E. coli and recombinant 
PgQC purified. The protein was crystalized, and structure determined by molecular 
vi 
replacement.  The rPgQC activity was characterized with respect to pH, ionic 
strength, optimum substrate specificity, and sensitivity to inhibition by an array of 
non-specific and specific inhibitors.  Finally, subcellular localization of PgQC in P. 
gingivalis was determined. Results: PgQC specificity is restricted for N-terminal 
glutamine.  The enzyme converts this residue to pGlu with kcat/Km at 1.34 s-1. The 
reaction was fastest at low ionic strength and at pH around 8.0.  The activity was 
inhibited by o-phenanthroline (≥100µM) and EDTA (≥100mM EDTA).  Cu2+  and 
Zn2+ at ≥100nM exerted ≥90% inhibition.  The activity was also significantly 
affected by cysteamine, imidazole, and reduced glutathione. In bacterial cells 
PgQC was found associated with the inner membrane as a lipoprotein facing the 
periplasm.  The crystalline structure of PgQC showed strong similarity to human 
QC on the atomic level. Nevertheless, an inhibitor specific for human QC had a 
limited effect on the PgQC activity. Conclusions: PgQC is an enzyme resembling 
mammalian QC and it is responsible for pyroglutamination of proteins secreted by 
the T9SS of P. gingivalis.  This activity is likely essential for bacterium viability 
since all attempts to produce a viable PgQC knockout failed.  Taking into account 
that also T. forsythia and P. intermedia possess similar enzymes and the frequency 
of the Q value of Bacteriodetes it is likely that similar post-translatonal modification 
plays a pivotal role in protein secretion by these periodontal pathogens.  Therefore, 
inhibition of bacterial QC may represent a novel approach to treat periodontal 
diseases.
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CHAPTER I: INTRODUCTION 
Periodontal Disease 
A periodontal diagnosis is a term that serves as a crucial determination of a 
patient’s dental treatment outcome. Clinicians assign these diagnoses on patients 
as a culmination of the sum of all the clinical information, pertinent medical history, 
and dental history along with the gross findings from a completed periodontal and 
oral examination. All the clinical data along with the totality of signs and symptoms 
are aggregated together and with this sum of information the clinician may arrive 
at a diagnosis. Additionally, sometimes in more complicated cases, additional lab 
tests or supplemental information can be instrumental in coming to the correct 
conclusion. As a clinician, treatment of plaque-induced periodontal diseases 
generally results in the resolution of the periodontal infection. Also, it is vital to 
understand that periodontal treatment generally changes the pretreatment 
diagnosis to a usually more favorable post-treatment diagnosis. To demonstrate, 
effective prophylactic treatment routinely converts mild, moderate, and severe 
plaque-induced gingivitis into a state of periodontal health, when stressed with 
adequate home care instructions. To further illustrate this point, successful 
treatment of plaque-induced periodontitis, when followed up at re-evaluation 
appointment, will often be converted to a state of periodontal health with reduced 
periodontium, indicating that treatment has achieved the goal of creating shallower 
pocket depth measurements.  
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Periodontal disease is term that encompasses multiple differential modalities into 
one general disease term. Within the diagnosis of periodontal disease, there are 
more diverse classification systems that both clinicians and researchers alike use. 
The most descriptive and thorough clinical classification system was described by 
Armitage in 1999, and is still utilized by clinicians today [1].  
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Table 1 Presentation of Periodontal Diseases in Humans 
Chronic Periodontitis (localized/generalized) 
Localized Aggressive Periodontitis (LAP) 
Generalized Aggressive Periodontitis (GAP) 
Periodontitis as a Manifestation of Systemic Disease 
    Associated with Hematologic Disorders 
    Associated with Genetic Disorders 
Necrotizing Ulcerative Periodontitis 
Combined Periodontic-Endodontic Lesions 
Abscesses of the Periodontium 
Armitage [1-3] 
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Most patients who present with plaque-induced periodontitis will in fact possess 
the chronic form of the disease [4-7]. The most likely presentation of a chronic 
periodontitis patient is a patient greater than 30 years of age; gross plaque and 
calculus, substantial gingival inflammation is present, deepened periodontal 
pockets (> 3mm), and the presence of calculated periodontal attachment loss. 
Generally speaking chronic periodontal disease is a slow continuously progressing 
disease[8-10], but within this process may exist short periods of advancing rapid 
attachment loss [11, 12]. Previously chronic periodontitis was given the misnomer 
“adult periodontitis” since only the adult population was believed to be susceptible 
to the disease. However, this has been shown to be false as a result of past and 
more recent epidemiologic data clearly showing that chronic periodontal disease 
can be present in younger populations [9, 13]. Although specifically chronic 
periodontitis can be observed to occur in either localized or generalized 
distributions within patients, these specific two forms appear to be vastly similar or 
almost identical with regards to their presentation, pathogenesis, and progression. 
Aggressive periodontitis, however, is far more rare than chronic periodontitis and 
mainly affects children and adolescents. It also can occur in both localized and 
generalized presentations, but unlike chronic periodontitis, these distributions 
differ significantly with respect to their pathogenesis [4, 13]. Localized aggressive 
periodontitis (LAP) and generalized aggressive periodontitis (GAP) were 




These different presentations of periodontal diseases are best described as 
multifactorial infections, which are elicited by the presence of an entire community 
of complex of bacterial species. This community of organisms referred to as a 
“biofilm” interacts with the host, specifically with connective tissue and immune 
cells, which in turn causes a release of large number of pro-inflammatory cytokines 
and chemokines. These pro-inflammatory mediators lead to the degradation and 
destruction of cellular structures of the periodontal organ, namely: bone, 
periodontal ligament, sulcular epithelium, and junction epithelium [15]. The trigger 
for the initiation of periodontal disease is the presence of dysbiotic microbial 
biofilms composed of bacteria that colonize the tooth surface in the sulcular region. 
This region lies between the tooth surface below the cement-enamel junction and 
the gingival margin and plaque formation is mediated through specific adherence 
interactions and accumulation due to architectural changes in the sulcus [16]. The 
characteristics of microbiological progression from periodontal health to gingivitis 
(e.g. chronic inflammation of the gingival tissue without tissue destruction), and 
eventually to periodontal disease are vast and complicated [17].  
Although it has been previously estimated that out of nearly 1,000 different 
microbial taxa are able to colonize, at least transiently the oral cavity of humans 
and from a complex organized biofilm [18], it is still not fully understood how the 
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multitude of different species exist and work harmoniously to begin the pathogenic 
process and progress to full blown disease state. Previous studies have shown 
that of the just under 1000 species detected in the oral cavity approximately 500 
are found to be present in periodontal plaque [19]. Some of these organisms most 
certainly are simply commensal or opportunistic species, but it is well documented 
that certain species drive the pathogenicity of the bacterial plaque into more 
virulent and destructive states [20]. Previous work has shown that even early 
colonizers and previously deemed commensals such as Streptococcus gordonii 
can have a profound effect on the pathogenicity of other organisms such as A. 
actinomycetemcomitans and Porphyromonas gingivalis [21]. It has been shown in 
several studies, and mentioned previously here that a multitude of bacterial 
species call the human mouth their home, humans overall understand very little 
about the consequences of harboring our bacterial inhabitants [22, 23]. Can the 
presence of just one of the “bad guys” turn our whole “neighborhood” into a difficult 
place to manage? Or does it take a combined effort of the community as a whole 
to corrupt our own host defenses. With regard to other dental diseases, such as 
dental caries, evidence is strong enough to allow us to point to the causative agent; 
Streptococcus mutans and Lactobacillus sp. Since these species have been 
identified, many papers have assessed the bacterial causative agents in patients 
in the varying states of periodontal health, gingivitis, and periodontitis [17, 20, 22, 
24, 25]. We are aware of a great many gram-positive bacterial species that serves 
as beneficial commensal species and serve to help maintain important oral health. 
We now also know that as the progression of the disease proceeds and heads 
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further towards gingivitis and chronic periodontitis, greater numbers of gram-
negative species begin to inhabit the sulcular epithelium and surrounding 
dentoalveolar structures. More striking though, is the simple fact that there is still 
no verifiable shown data, that one solitary species can solely cause the wide-
ranging effects that periodontal disease can elicit in the mouth. No one organism 
can account for the varied destructive processes that occur in the disease process. 
This leaves us with the thought that the disease can only progress if several 
bacterial species join forces and the signs and symptoms of periodontal disease 
are in fact the result of a group effort. It must be clear then that a specific “consort” 
or “complex” of bacterial species must trigger the transition from a state of oral 
health to periodontal disease. Innumerable studies have focused on one specific 
bacterial species responsible for signs and symptoms of periodontal disease, but 
these do not account for the whole story. This, taken as a whole, supports the 
notion that the effects from periodontal disease must be the result of consortia of 
bacterial species acting as a complex biofilm to cause, elicit, and promote the 
disease [24-27]. Recently there has been reassessment of the “roles” of several 
bacterial species that are known to be involved in the progression of periodontal 
disease. These organisms were routinely found in examinations of patients who 
presented with periodontal disease and also in healthy controls. These species are 
now even commonly referred to as periodontopathogens. Included in this group 
are P. gingivalis, A. actinomycetemcomitans, T. forsythia, and T. denticola.  
Influential studies by Socransky and Haffajee [24] used newer methodology of 
stratifying these bacteria into their respective niches based on their roles within 
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oral microbiomes in the disease process leading to change from health to disease 
states.  Researchers organized the organisms into groups or “complexes”. 
Individual complexes were based on the prevalence of the bacterial “affiliations” 
with one-another, and corresponding complexes associations with health, 
gingivitis, or periodontitis disease conditions [25-29]. These groups or complexes 
of different microbes were also stratified according to the sequence of colonization 
on the tooth surface in conjunction with periodontal disease severity. What 
Socransky et al. [20] labeled as the ‘red complex’ contained bacterial species that 
show up later in biofilm maturation phase. These bacterial species, namely, P. 
gingivalis, T. denticola, and T. forsythia (previous names Bacteroides 
forsythus or Tannerella forsythensis) were shown to be effective 
periodontopathogens [11, 20, 24, 26, 30]. In this same train of thought these 
investigators also concluded that this “red complex” represents the pinnacle of 
biofilm maturation and development and thus leading to advancing disease states. 
Multiple other researchers have made note of this cooperation between species 
within the same complex and between members of different complexes. A strong 
association has been observed between T. forsythia and P. gingivalis found in 
periodontal pockets in patients, whilst in fact P. gingivalis has not been detected in 
the absence of T. forsythia within the periodontal pocket [31]. A strong relationship 
between P. gingivalis and T. denticola was found whilst taking plaque samples 
gathered in a study looking at diverse ethnic groups [32]. Moreover, constituent 
members of the red complex were located in significantly higher percentages in 
patients with periodontitis [33, 34] and also in probing sites with deeper pockets 
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[35-40]. These separate bodies of work support the theory that no one single 
bacterial species is etiologic for periodontal disease propagation or progression, 
and periodontal disease is not a singular “bacterial infection” but instead that the 
sum total of bacterial species in the oral cavity co-existing and co-habituating the 
oral microbiome are required to initiate the onset of periodontal disease. How these 
different species and organisms, as well as virulence determinants of the individual 
bacteria, contribute to disease progression remains unclear. Another hypothesis 
in more recent years has challenged the way we typically look at the “complexes” 
of oral microbiota in the mouth. While looking at the red complex organisms one 
would beg to ask the question, would higher numbers of these organisms correlate 
with greater periodontal tissue destruction. In fact, certain pathogens, more 
specifically, some from the red complex are actually found to be present in low 
numbers. More recently, multiple analyses of the human microbiome have started 
to shift the focus on biofilms away from consideration as a true “infection” but 
instead as a dysbiotic disease. We are beginning to live in the age of the dysbiotic 
inflammatory disease. Dysbiosis is a process by which communities of normally 
healthy bacterial species become unstable and unregulated and in response drive 
the inflammatory process. This outlook has become more optimal a term to assign 
to periodontal disease than just giving few species the honor of being disease 
causing agents. In healthy individuals, oral microbiota remains in a state of 
harmony and regulation, but in susceptible individuals or compromised patients, 
dysbiosis can lead to unfavorable and harmful host-microbial interactions and 
eventually leads to periodontal inflammation and destruction of the periodontal 
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tooth supporting structures [41-43]. This in turn leads to the inflammatory reaction 
products being released into the gingival crevicular fluid (CGF) which then 
promulgates and promotes furthering the disease process [44-46]. This cycle of 
inflammation and dysbiosis could be a key factor that plays into periodontal 
disease’s main components, its lasting effects and difficulty to treat. Traditional 
therapy of scaling and root planning for periodontal disease, along with 
debridement and maintenance of the oral cavity may now be possibly augmented 
to include adjuvant therapies that target this dysbiotic shift towards more 
pathobiont species [47, 48]. In addition to this potential benefit, some of released 
host factors or molecules could have utility as disease markers in patient 
treatment. This could serve to reflect a more accurate disease state or give a 
better indication of the level of periodontal inflammation and disease progression 
than was previously available by solely clinical examination [49].  
The keystone pathogen hypothesis was posited as a result of new information 
coming to light in the field. Studies showed that conversely, relatively low level of 
the red complex species were actually present in biofilms, and in the mice bone 
loss model suspected periodontopathogens were only needed in small numbers 
to influence periodontal inflammation and bone loss [50, 51]. The small bacteria 
cell count were enough to initiate a shift in the number and makeup of the complex 
biofilm. This alteration of the biofilm composition occurred before the onset of 
significant bone loss and was closely associated with the colonization of P. 
gingivalis, indicating that the cause of the disease was the shift in bacterial species 
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composition or dysbiosis not solely the offending organisms’ presence alone [51]. 
This in conjunction with the observed fact that P. gingivalis, in the absence of other 
commensal bacteria, fails to cause periodontitis in mice. For the purposes of this 
dissertation, our discussion will focus mainly on the periodontopathogen and 
keystone pathogen, P. gingivalis, its associated virulence factors, and the methods 
by which these are manufactured and undergo post-translational modifications.  
Poprhyromonas gingivalis 
P. gingivalis, as mentioned above, has been a heavily studied pathogen in the oral 
cavity and will be mainly the subject of this dissertation. As mentioned previously 
we label this bacterium as a keystone pathogen in human periodontitis [50, 52]. By 
placing this moniker on this bacterium, we imply that this organism is capable of 
causing dysbiosis. The dysbiosis can manifest in the form of either relative number 
or abundance of pathogenic species or change in the role or stratum of the species 
within the biofilm, even at low microbial levels within the biofilm. Microbial analysis 
studies have shown that despite its known importance in oral biofilm, P. gingivalis 
is only a minor constituent of periodontal disease-associated biofilms [53-55]. This 
is further confirmed by studies showing that, in a mouse model of periodontitis, P. 
gingivalis was able to colonize in low-levels and was shown to cause an increase 
in certain populations of the periodontal microbiota followed by inflammation-
driven alveolar bone loss [51]. In addition, serving as a keystone pathogen comes 
with certain responsibilities such as serving a specialized role in the biofilm 
community. This role coordinates and modulates the activity of other organisms 
within the plaque and plays an essential role in its pathogenicity [56, 57]. In this 
12 
role, P. gingivalis influences the transition from mainly commensal bacteria into a 
pathogenic biofilm [52]. P. gingivalis is a Gram-negative, obligate anaerobe, and 
asaccharolytic rod which possess a number of virulence factors [58-60]. Many of 
these virulence factors are directly related to P. gingivalis’ ability to subvert the 
host immune system. The use of these virulence factors is what makes P. 
gingivalis an effective pathogen. 
Gingipains 
Some of these virulence factors alluded to previously are the proteases, 
gingipains. Included in this category are the arginine-specific gingipains [Arg-
gingipain-A (RgpA) and Arg-gingipain-B (RgpB)] and also the lysine-specific 
gingipain [Lys-gingipain (Kgp)]. These are encoded respectively by their three 
constituent genes within the P. gingivalis chromosome commonly referred here as 
rgpA, rgpB and kgp which are heavily conserved among different clinical and 
experimental strains of P. gingivalis [61]. The products of the translation of these 
genes (specifically the rgpA and rpgB), RgpA and RgpB, both contain a caspase-
like domain (that retains specificity for Arg-Xaa peptide bonds) and an 
immunoglobulin-like domain. Uniquely in the proteinase RgpA, the protease and 
Ig-like domain is subsequently followed-up with a large hemagglutinin-adhesin C-
terminal extension. Closely related to the above protein, the kgp gene-translation 
product, Kgp, contains a catalytic domain specific for Lys-Xaa peptide bonds and 
also contains a hemagglutinin-adhesion domain not too unlike the rgpA translation 
product. [62, 63], RgpB lacks the hemagglutinin-adhesin domains but the short C-
terminal domain is conserved. Gingipain translation products undergo heavy post-
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translational modification. Nascent translation products encompass a pro-
fragment, a catalytic domain, an Ig-like domain, hemagglutinin-adhesion domains 
(only in RgpA and Kgp) and the conserved C-terminal domain (CTD). During 
secretion of RgpB, the pro-fragment is proteolytically removed and subsequent 
processing of the CTD reveals the active catalytic domain followed by the Ig-like 
domain. Subsequent glycosylation and incorporation to the outer membrane 
surface occurs afterwards. In the case of RgpA and Kgp similar processing occurs 
but the hemagluttanin-adhesin domains remain non-covalently associated with the 
catalytic domain. Lastly, gingipains once processed are secreted either as a 
monomeric form specific to the case of RgpB, or as complexes of protease and 
hemagglutinin-adhesin domains in the case of RgpA and Kgp. These complexes 
are either predominantly attached to the bacterial surface or released into the 
medium in a soluble form. This is dependent on a P. gingivalis strain, for example 
the strain HG66 secretes soluble gingipains freely into the media. Gingipain 
activities serve as meditators for nutrient acquisition, serve to cleave receptors on 
the host cell surface, and moreover, avoid and subvert the host immune system 
by inactivation of cytokines and components of the complement system. One of 
the most profound changes observed in patients with clinical periodontal disease 
is the aberrant remodeling of the host periodontal tissues. Structural changes that 
are often associated and observed with advanced periodontal disease include 
alveolar bone resorption and periodontal ligament destruction. These changes in 
structure in turn lead to attachment loss and periodontal pocket formation and 
eventually tooth loss. Periodontal pockets found in patients with periodontal 
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disease are also lined with epithelial cells that have had alterations, making them 
distinctly different from healthy cells that form the junctional epithelium found in the 
healthy periodontium. To accomplish this tissue-remodeling host cells require 
proteolytic degradation of important structural elements and extracellular matrices 
such as the collagen fibers forming the periodontal ligament and proteins involved 
in cellular junctions and extracellular matrix proteins [64-67]. The mechanism by 
which gingipains play a role in this process is complex and beyond the scope of 
this introduction. But in summary gingipains are important both directly and 
indirectly involved in the pathological tissue remodeling associated progressing 
disease process of periodontitis. Nevertheless, it is most likely that gingipains are 
not solely involved as the major virulence factor in periodontal disease tissue 
destruction [59]. It is instead much more probably that these proteases synergize 
with other mechanisms and virulence factors used by P. gingivalis and other 
bacteria and disrupt the host proteolytic balance and interfere with endogenous 
host protease inhibitors. Once this balance has been disrupted, host proteases, 
namely MMPs, TIMPs, and neutrophil elastase, drive the response in the 
periodontium for accelerated remodeling and pathological destruction of the host 
tissues[64, 68]. The effects of gingipains have been studied in great details and 
the role that they play in the disease process is expanding [59]. This variable output 
of potent virulence factors gives P. gingivalis quite an arsenal with which to exert 
effects into the host organism and biofilm community. 
Protein Secretion Systems of Bacteroidetes Species 
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Apart from the Sec pathway that exports proteins into or through the inner 
membrane [69, 70], the armamentarium of well-characterized secretion pathways 
of Bacteroidetes is surprisingly limited. Bacteroidetes possess both type 1 and type 
6 secretion systems (T1SS and T6SS) that are responsible for secreting proteins 
to extracellular environment bypassing the periplasm. Recently, there has been a 
great deal of effort produced to characterize the T9SS. This system is typical for 
Bacteroidetes and rarely, if ever, found outside the phylum [71, 72]. The T9SS 
machinery transports proteins across the outer membrane, which were first 
exported into the periplasm via the Sec translocon.  All proteins secreted by T9SS 
possess a characteristic C-terminal domain (CTD) that codes for transportation 
through the outer membrane [71, 73]. The processes that are undertaken 
upstream of CTD-dependent secretion have garnered less investigation, mainly 
due to their ubiquity in other organisms and Bacteroidetes and have been 
extensively studied in gram-negative bacteria in general [70]. We report here that 
these upstream processes are unique to Bacteroidetes and do in fact merit 
attention. To put this more into perspective, some background on the Sec 
translocon is helpful.  
The Sec pathway identifies target proteins by the presence of a signal peptide [74]. 
These signal peptides contain a tripartite architecture. They consist of a positively 
charged N-terminal region, which is thought to designate proteins to the 
phospholipid membrane, a hydrophobic region, which is hypothesized to be 
inserted into the membrane, and finally a shorter region that often contains a 
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consensus motif for a signal peptidase [75, 76]. Proteins that contain signal 
peptides can escape from the Sec translocase in two different ways. If they 
manage to escape “laterally”, they will then become contained within the inner 
membrane [69]. The other way would have them reach the periplasm, but the 
signal peptide portion is not cleaved and remains in the inner membrane. This 
leaves the proteins’ C-terminal end (with a signal peptide cleavage site) exposed 
on the periplasmic surface of the inner membrane [75]. The eventual fate of 
proteins that reach this stage will depend on the type of the signal peptide 
contained within. 
Proteins that carry a type I signal peptide are released from their membrane 
anchored signal peptide by signal peptidase I (SPI) [74, 75]. They will subsequently 
remain in the periplasm, or if necessary be transported further, for example, by a 
T9SS through the outer membrane, ultimately destined for the surface of the outer 
membrane or for release into the environment [71]. Proteins which carry a type II 
signal peptide undergo processing differently. A diacylglyceryl transferase (termed 
Lgt) first attaches a diacylglycerol membrane anchor to the cysteine residue which 
resides immediately downstream of the signal peptide [77]. Secondly, signal 
peptidase II (SPII) (also known as lipoprotein signal peptidase or Lsp) can cleave 
a lipoprotein upstream of the modified cysteine residue [78, 79]. Occasionally, 
lipoproteins can remain attached to the inner membrane while others are 
transported to the outer membrane via the Lol system [80]. Thus, lipoproteins 
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found in gram-negative bacteria are generally periplasmic proteins which are 
anchored either to the inner or outer membrane of the bacteria.  
The N-terminal residue of proteins is frequently chemically modified, and these 
modifications often have a signaling role. If an N-terminal glutamine residue is 
exposed as a result of proteolysis, these glutamine residues have the capability to 
spontaneously cyclize to pyroglutamate, with concomitant release of ammonia as 
a side product. The reaction is also facilitated by inorganic catalysts such as 
phosphate ions serving as the proton shuttle, and furthermore, can be catalyzed 
enzymatically by glutaminyl cyclases (QCs) [81].  
Glutaminyl Cyclase 
As one of the enzymes for protein post-translational modifications, glutaminyl 
cyclase (QC; glutaminyl-peptide cyclotransferase (QPCT), EC 2.3.2.5) is an 
acyltransferase that catalyzes N-terminal pyroglutamate (pGlu) formation on 
proteins or peptides and the concomitant release of ammonia or water molecules 
see Figure 1 [82].  
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Fig. 1: N-terminal cyclization of glutaminyl peptides by QC. Glutaminyl containing 
peptide is cyclized in the presence of QC by formation of an intermediate state that 
culminates in the release of ammonia.  
N-terminal cyclization of glutaminyl peptides by QC.
Stephan Schilling et al. J. Biol. Chem. 
2003;278:49773-49779 
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The cyclization of L-glutamine into pyroglutamate is considered a quasi-
irreversible intramolecular acyl transfer reaction. The N-terminal peptide amino 
group is responsible for a nucleophilic attack on the γ-carbon amide, forming a 
tetrahedral intermediate. Subsequent decomposition of this intermediate occurs 
from net 1,3-proton transfer from Nα onto a leaving ammonia, forming the pGlu 
ring. This cyclization or modification appears to be involved in the structural 
stability of secreted proteins, resistance to aminopeptidase degradation, and 
hypothetically play an important role in mediating receptor binding [83]. QC is a 
catalytically non-discriminatory enzyme; acting upon an availably N-terminal 
glutamine residue, although it does exhibit slight preference for substrates 
containing a penultimate bulky hydrophobic residue [84]. Recently it has been 
shown that phosphate ions in conjunction with QC are able to operate as a 
coordinated proton transfer system. This system is able to effectively increase the 
rate of cyclization by QCs. Possibly; phosphate acts as a dual functioning acid–
base catalyst to increase the proton transfer rate, where simultaneous protonation 
and deprotonation occur together in conjunction with a cyclic-ring transition state 
(Fig. 2 A and B). Previously phosphate ions have been hypothesized to serve as 
dual functioning catalysts during the iminolactone hydrolysis [85] or for thiamin 
enzyme tautomerization [86]. Acid–base catalysis is the primary source of 
catalysis used by QCs. The proposed role of the active-site zinc ion in QC can be 
nicely correlated to the above-described rate-limiting trapping of T ± in acyl 
transfer reactions in solution (Fig. 2 B). The active site zinc functions as a strong 
Lewis acid, and proton transfer from the attacking α-amino group to the leaving 
20 
ammonia is accelerated by a glutamic acid moiety in conjunction with two other 
acidic residues, as suggested by QC crystal structures [87, 88].  
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Fig. 2: Hypothetical role of phosphate (A and B) and QC (C) in acceleration of 
glutaminyl cyclization. Phosphate ions facilitate the proton transfer onto the leaving 
ammonia. The catalysis might involve facilitated proton transfer onto the oxanion 
(A) or deprotonation of the attacking α-amino group (B). The proton transfer in QC 
is facilitated by a glutamic acid residue. A significant acceleration of the reaction is 
achieved by “trapping” of the oxanion by the active site zinc ion. Possibly, the 
proton transfer from the attacking alpha-amino group to the leaving ammonia 
occurs simultaneously [89]. 
QC was originally discovered in dried latex belonging to the Carica papaya (CpQC) 
plant species [90]. Glutaminyl cyclases (QCs) have been demonstrated in multiple 
plant and bacterial species and share a common ancestry [91-94]. It has been 
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found that the known mammalian QCs are either Golgi-resident or freely secreted 
enzymes [93]. Several peptide hormones and proteins carry N-terminal 
pyroglutamyl residues. Until somewhat recently, the cyclization of L-glutamine 
peptides’ N-terminus into pyroglutamate was thought to occur spontaneously [95]. 
This cyclization was shown that the conversion occurs under physiological 
conditions but at a very slow rate, therefore necessitating the need for enzyme 
catalysis [96]. Mammalian and plant QCs, however, have been discovered to serve 
as this executor of the reaction [97-101]. In general, both mammalian and plant 
QCs appear to have similar molecular masses, ~33 and ~40 kDa, respectively, 
and both are monomeric proteins [102, 103]. The primary structures of the 
proteins, however, display no sequence similarity, and the secondary structure of 
the individual QCs are completely different. The plant CpQC and the related QC 
from bacterial plant pathogen Xanthomonas campestris (XcQC) adopt a five-
bladed beta-propeller fold [104]. As one would expect for beta-propeller proteins, 
the active site is located near the propeller axis [105].. Mammalian QCs however 
are shown to encompass an α/β-fold [106-108]. In addition, currently identified 
plant QCs do not share sequence homology to other known plant enzymes, which 
places them into a separate enzyme family or subfamily [100]. On the other hand, 
identified mammalian QCs possess clear homology toward known bacterial 
aminopeptidases, thus suggesting possible the evolutionary origin of the protein 
family [107]. The mechanism of catalysis for plant QCs is much less clear than for 
mammalian QCs. In mammalian QCs, the cyclization reaction serves its function 
during maturation of numerous cytokines and neuropeptides in the secretory 
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pathway, such as gonadotropin-releasing hormone (GnRH), thyrotropin-releasing 
hormone (TRH), and monocyte chemotactic protein-2 (MCP-2). The theoretical 
role of the pGlu residue on these peptides is believed to serve two functions; (1) 
protecting the peptides from peptidase degradation and (2) providing the proper 
conformation of the peptide to facilitate receptor binding [109, 110]. Uncontrolled 
expression of QC in humans (HsQC) has been shown to be related to certain 
pathological conditions, for example Alzheimer disease [111]. Site-directed 
mutagenesis and X-ray crystallography studies of recombinant HsQC have given 
us large amounts of information about the catalytic mechanism of QCs [112, 113]. 
Furthermore, HsQC has been used as a target for inhibitors, which have been 
synthesized and developed as drugs to treat the relevant diseases that occur from 
their overabundance [94, 114]. QCs have also been shown to be present in a 
number of snake venom isolates [115] in keeping with finding that proteins and 
toxins in snake venoms are often resistant to Edman-degradation during sequence 
analysis. Cases that have been shown include bradykinin-potentiating peptides 
[116, 117], metalloproteinase inhibitors [118], and endogenous metalloproteinases 
[119]. Based on current literature, human QC is thought to share the scaffold of 
known bacterial aminopeptidases [120]. This is in contrast to the fact that all the 
putative QCs thus far identified in bacteria share homology with plant QC. When 
analyzed by atomic absorption spectroscopy, HsQC has been shown to contain 
one zinc ion per HsQC molecule [121]. Competitive inhibitors of HsQC have been 
identified, such as heterocyclic compounds (imidazole, tetrazole, and triazole 
rings). This is most likely due to nitrogen atoms serving as good coordinators of 
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the active-site zinc ion found in QC [122, 123]. Solely the fact that HsQC could be 
inhibited/inactivated by heterocyclic inhibitors suggests that the zinc ion located 
within the QC is essential for catalytic activity [94]. In stark contrast, the same 
heterocyclic chelators display no inhibition of plant QCs [103]. Considering this 
information together, both plant and mammalian QCs are thought to belong to two 
different enzyme families with different ancestral origins [100]. While mammalian 
QCs are implicated in the maturation of numerous neuropeptides and cytokines, 
such as thyrotropin-releasing hormone (TRH) and gonadotropin-releasing 
hormone (GnRH) [102, 124, 125], the physiological function of plant QCs remains 
poorly characterized. Recently, it has been suggested that plant QCs could be 
involved in defense mechanisms [126, 127], a hypothesis that is supported by the 
observation that the quantity of plant QC expressed increases greatly as a result 
of repeated injury [127]. The role of QCs in both bacteria and parasites has not 
been studied in depth. Advances in methodology for QC activity assays [128] and 
the discovery of new HsQC inhibitors [114, 129] have rendered better tools to 
explore QCs. A new QC has been isolated from P. gingivalis and its role has been 
examined for the first time. Structural homology models of known QCs were 
generated and compared. Furthermore, we successfully cloned and sequenced 
the QC cDNAs from P. gingivalis and compared the sequence with that of human 
and other animal QCs. In addition, we also examined the optimal pH range, 
stability, and the effects of metal chelators, metal ions, and finally examined 
specific QC inhibitors on the representative bacterial QC. These QCs share similar 
catalytic activity but structurally remain distinctly different. [113, 126]  
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In studying the proteome of P. gingivalis and its novel T9SS, protein sequences 
destined for secretion via the T9SS with the conserved C-terminal domains (CTDs) 
that facilitate secretion from through the outer membrane complex [73]. 
Approximately 30 CTD-bearing proteins exist in P. gingivalis genome and these 
proteins all contain this conserved C-terminal domain [73]. Recently it has been 
demonstrated that the CTD-containing proteins are secreted and attached to the 
cell surface via the type IX secretion system (T9SS) [73, 130-132]. These CTD-
bearing proteins undergo extensive post-translational modifications before 
attachment to the surface. Belonging to this group of CTD-containing proteins are 
the gingipains (RgpB, HRgpA, Kgp), which are major virulence factors of this 
periodontopathogen [133]. Upon examination of the sequences of these T9SS 
cargo proteins it can be observed that a N-terminal Gln residue is present just after 
the N-terminal signal peptide. Mass spectrometry analysis of these secreted 
proteins revealed that after post-translational modification, a pGlu residue is 
present at the N-terminus of the mature protein. This led us to hypothesize the 
existence of a bacterial QC present in P. gingivalis, responsible for this cyclization 
of Gln to pGlu. The presence of proteins containing N-terminal pyroglutamate 
residues has been noted in previous proteomic studies on Bacteroidetes species 
[73, 134-137]. At the outset of this study, we became aware of a drastic 
overrepresentation of glutamine residues after SPI cleavage sites in P. gingivalis. 
Starting from these two observations, we aimed to (1) clarify the pathway of 
pyroglutamate formation, (2) determine the fraction of SPI substrates that could be 
cyclized, (3) estimate the fraction that is actually cyclized, (4) test a possible role 
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of pyroglutamate formation in sorting, initially for P. gingivalis only, and then for 
Bacteroidetes in general, (5) characterize the function and importance of PgQC 
within the T9SS. The function and purpose of the PgQC is hypothesized. In this 
dissertation, we attempt to verify the existence, explain the purpose and role of QC 
in P. gingivalis, and reveal its potential importance in the secretion pathway in P. 
gingivalis and other Bacteriodetes. 
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CHAPTER II: MATERIAL AND METHODS 
Proteomes and taxonomy information were taken from UNIPROT [138]. Signal 
peptides and cleavage sites were predicted using the batch version of 
SIGNALP4.1 [139]. Lipoproteins were predicted using LipoP1.0 [140]. Sequence 
logos were generated using the program Weblogo [141]. Intersections between 
proteins with predicted signal peptide and predicted lipoproteins were using the 
UNIX comm tool. Since not all UNIPROT species have been fully identified, some 
species names such as “Tannerella sp.” were encountered. 
Cloning, expression and purification of recombinant PgQC 
The QC protein was expressed as a GST-tag fusion protein. Briefly, the entire 
coding region of qc identified by BLAST search (PG_2157) was amplified from a 
P. gingivalis W83 genome template with Platinum Taq DNA Polymerase High 
Fidelity (Invitrogen) using primers F1_QC: 
ATTAGAATTCATGAAAAGACTGATAACAACAGGAG and R2_QC: 
ATTACTCGAGTCAGTGTGAAGCGGCTTTCACCTGTTCG. The 1001 bp PCR 
product was digested with EcoRI – XhoI and cloned downstream in-frame with the 
sequence encoding gluthatione S-transferase (GST), into EcoRI – XhoI digested 
pGEX-6P-1 expression vector (GE Healthcare).  Following confirmation by PCR, 
resulting expression pGEX/QC vector was transformed into E. coli Bl21 (DE3) 
expression host. Transformed E. coli cells were grown in LB media at 37° C until 
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OD600 0.6, cooled down to 24 °C and expression of recombinant protein was 
induced with 0.1 mM isopropyl-1-thio-β-galactopyranoside (IPTG). After overnight 
cultivation, cells were harvested by centrifugation (6,000 x g, 20 min), resuspended 
in PBS supplemented with lysozyme, and lysed by sonication (3 cycles of 10 x 3 s 
pulses at 17 W). Cell lysate was clarified by centrifugation (30,000 x g, 30 min) and 
loaded onto a pre-equilibrated glutathione-SepharoseTM High Performance 
column. Recombinant GST-QC fusion protein was eluted using 50 mM Tris-HCl, 
pH 8.0, supplemented with 10 mM reduced glutathione. The purified GST-QC 
protein was subsequently incubated with PreScissionTM Protease (GE Healthcare) 
and subjected again to chromatography on glutathione-SepharoseTM to remove 
the GST tag. The purity of the resulting protein was verified by SDS-PAGE 
electrophoresis (NuPAGER 4-12% Bis-Tris Gel, Invitrogen). Protein concentration 
was determined by BCA Assay (Sigma). 
PgQC activity assay 
The activity of PgQC was determined essentially as previously described (33). 
Briefly, 150 μl of the assay buffer (40 mM Tris-HCl, 400 mM KCl, pH 8.0), 10 μl of 
chromogenic substrate (200 mM H-Gln-AMC in DMSO), and 10 μl of a 
recombinant bacterial pyroglutamyl aminopeptidase (25 U/ml, Unizyme 
Laboratories, Hørsholm, Denmark) were mixed together in a microtitration plate 
and preincubated 10 min at 30°C.  The reaction was initiated by addition of 30 μl 
appropriately diluted purified rPgQC or P. gingivalis whole culture or washed 
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bacterial cells or subcellular fractions and after 1 min incubation the increase in 
fluorescence (lex = 380 nm, lem = 460 nm) was recorded for 10-20 min at 30°C. 
Unspecific cleavage of the H-Gln-AMC substrate was determined by omitting 
pyroglutamyl aminopeptidase, the auxiliary enzyme. If necessary, the unspecific 
cleavage was subtracted from PgQC activity. Metal-ion inhibition reactions were 
carried out in similar fashion with each respective inhibitor added to the reaction 
mixture prior to initiation of the assay. 
P. gingivalis culture and cell fractionation procedures 
P. gingivalis culture fractionation was performed at 4°C as described previously 
[142] starting from stationary-phase (a 2-day-old) cultures adjusted to an OD600 of 
1.5.  Briefly, cells were collected by centrifugation at 6,000 × g for 15 min, washed 
once with phosphate-buffered saline (PBS), and resuspended in 5 ml of 0.25 M 
sucrose and 30 mM Tris, pH 7.6. After mixing gently for 10 min cells were 
repelleted at 12,500 × g for 15 min. The outer membrane was disrupted by the 
rapid addition of ice-cold distilled H2O and the spheroplasts were pelleted by 
centrifugation at 12,500 × g for 15 min.  The supernatant was designated the 
periplasmic sample. The remaining spheroplast pellet was resuspended in 5 ml 
PBS and ultrasonicated in an ice-water bath. Cellular debris and membranes were 
pelleted by ultracentrifugation at 150,000 × g for 1 h, and the supernatant was 
designated the cytoplasmic sample. The remaining pellet was washed and 
resuspended in cold PBS by sonication.  This fraction was designated the 
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membrane sample. For individual membranes separation washed collected cells 
were lysed by ultrasonication as described above. The membranes were pelleted 
by ultracentrifugation (150,000 × g, 1 h) washed with PBS to remove periplasmic 
and cytoplasmic proteins and resuspended in PBS by sonication. The inner 
membrane was dissolved with Sarkosyl (lauryl sarcosine) and the residual 
Sarkosyl-resistant outer membranes (OM) were pelleted by ultracentrifugation 
(150,000 × g, 1 h).  The supernatants were designated the IM samples while 
pellets washed and suspended by sonication in PBS were designated the OM 
samples. Purity of the various fractions was checked by Western blotting for A-
LPS or gingipains and the biotin containing 15 kDa biotin carboxyl carrier protein 
(AccB alias MmdC or PG1609) as OM and IM specific markers, respectively [62, 
143] (data not shown). 
Generation of P. gingivalis ΔRgpB deletion mutant 
For subsequent analysis, generation of plasmids suitable for rgpB gene 
mutagenesis the pRgpBall master plasmid was first engineered based on the 
pURgpB-E construct [142]. A partial rgpB gene section upstream of the 
erythromycin cassette was replaced with whole rgpB coding sequence, together 
with an 817 bp fragment containing its potential promotor. The new fragment was 
amplified with primers RgpBall_F and RgpBall_R using genomic DNA of P. 
gingivalis W83 and ligated into the linearized pURgpB-E plasmid (with EcoRI and 
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SmaI restriction enzymes) by the Gibson’s method [144] resulting in pRgpBall-erm 










































RgpAQ1N Fs ACGCAATCCGAATGTGAGATT 
RgpAQ1N Ft GAACCAGACAGAGTTGGGACGCA
ATCCGAATGTGAGATT  


























Table 2: Primers used for construction of plasmids for P. gingivalis mutagenesis. 
Next, the RgpB deletional plasmid (pRgpBdel-erm) was obtained by the truncation 
of pRgpBall-erm plasmid using the PCR based Site-directed, ligase-independent 
method (SLIM) [145] with primers listed in Table 2. With this approach, only the 
small fragment of 3’ (154 bp) of rgpB CDS was preserved on the pRgpBdel-erm 
plasmid. The ΔRgpB strain was obtained in the homologous recombination event: 
the plasmid was elecroporated into the P. gingivalis W83 strain and the positive 
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recombinant clones were selected with 5 µg/ml erythromycin. Proper 
recombination was verified by sequencing. 
Generation of P. gingivalis gingipains Q mutants 
Mutagenesis of each gingipain required a dedicated master plasmid. For RgpB 
studies the pRgpBall-erm construct was used. The Q1N mutation (replacement 
CAG codon into AAC) was incorporated using the SLIM method (resulting in the 
pRgpBallQ1N-erm plasmid), the Q25A mutation (replacement of the CAG codon 
into GCT) was introduced by the QuikChange method (Stratagene) (generating 
pRgpBallQ25A-erm), all sequences of applied primers are listed in Table X in the 
RgpBQ1N section. These plasmids were introduced into the P. gingivalis W83 
RgpA-C strain lacking the whole rgpA gene [142] by the electroporation and the 
recombined clones were selected with 5 µg/ml of erythromycin. The obtained 
strains were partially sequenced and named ΔRgpA/RgpBQ25N and 
ΔRgpA/RgpBQ25A, respectively. 
For RgpA mutagenesis, a master plasmid pNRgpA-tet was engineered. Two DNA 
fragments were amplified from P. gingivalis genomic DNA. The upstream 915 bp 
fragment consisting of sequence directly adjacent to the RgpA promotor was 
amplified with primers RgpA_Up_F and RgpA_Up_R). A downstream 2835 bp 
fragment, comprising the 5’ sequence of the RgpA gene together with 388 bp of 
its proposed promotor was amplified with primers RgpA_Dw_F and RgpA_Dw_R. 
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The tetracycline (tetQ) resistance cassette was amplified from the pT-COW 
plasmid [146] with primers Tet_BamHI_F and Tet_SalI_R. The backbone, the 
pUC19 plasmid, was linearized by PCR reaction with primers puc_EcoRI_R and 
puc_HindIII_F. All four amplified fragments were combined in the single step 
reaction by the method described by Gibson [144]. The Q24N mutation 
(replacement cag codon into aac) was incorporated to the construct with the SLIM 
method. Sequences of applied primers are listed in Suppl. Table 1 (RgpAQ24N 
section). This plasmid was introduced into the P. gingivalis W83 ΔRgpB strain 
lacking the whole rgpB gene by the electroporation and the recombined clones 
were selected with 1 µg/ml of tetracycline. Obtained strain was partially sequenced 
and named RgpBdel/RgpAQ24N. The non-mutated master plasmid was also 
introduced into the ΔRgpB strain P. gingivalis W83 and the unaffected expression 
and activity of RgpA was observed. 
For Kgp mutagenesis, the pNKgp-cep master plasmid was created in a similar 
manner. First, two fragments adjacent to the start of the hypothetical Kgp promotor 
were amplified from the genomic DNA, the 809 bp upstream fragment with 
Kg_Up_F and Kg_Up_R primers, while the 3271 bp downstream fragment with 
Kg_Dw_F and Kg_Dw_R primers. The beta-lactamase gene cepA was amplified 
with primers CepA_F and CepA_R from template synthetized by the Life 
Technologies based on the sequence deposited under AAA21538.1 number 
(Gene Bank). The pUC19 plasmid was linearized with primers pUC_SphI_R and 
pUC_BamHI_F. The Q20N mutation (replacement caa codon into aat) was 
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incorporated to the construct with the SLIM method. Sequences of used primers 
are listed in Suppl. Table 1 (KgpQ20N section). This plasmid was introduced into 
the wild type P. gingivalis W83 by the electroporation and the recombined clones 
were selected with 2 µg/ml of ampicillin. Obtained strain was partially sequenced 
and named KgpQ20N. As a control, the non-mutated master plasmid was also 
electroporated into the P. gingivalis W83 strain and the unaffected expression and 
activity of Kgp was observed. 
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Fig 3: P. gingivalis mutant strains. A) schematic representing RgpBdel-erm. B) 
RgpA-tet C) Kgp-cep. Schematic representation of steps undertaken to generate 
P. gingivalis mutant strains. 
Gingipain activity assay 
The amidolytic activities of Rgp and Kgp enzymes were assessed by the hydrolysis 
of the chromogenic substrate benzoyl-L-arginine-p-nitroanilide (BApNA) and 
carboxybenzoyl-L-lysine p-nitroanilide (zKpNA; Novabiochem, Germany), 
respectively. In a 96-well format, 20-μl samples were preincubated in assay buffer 
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(200 mM Tris-HCl, 100 mM NaCl, 5 mM CaCl2 [pH 7.6][71], supplemented with 
fresh L-cysteine to 10 mM) for 2 min prior to the addition of 1 mM substrate in a 
total volume of 200 μl. For activity measurement of Sarkosyl-treated membrane 
fractionations (see Materials and Methods), a 0.125 mM concentration of a 
synthetic arginine substrate pyro-glutamyl-glycyl-L-arginine-p-nitroanilide 
(pyroEGRpNA; Pharmacia-Harper, Uppsala, Sweden) was used instead of BApNA 
due to precipitation of the BApNA substrate in the presence of the Sarkosyl 
detergent. The presence of 0.1% Sarkosyl detergent in the assay did not affect the 
rate of substrate hydrolysis as determined with purified RgpB (data not shown). 
The rate of formation of p-nitroanilide was measured at 405 nm using a 
SpectraMax Plus spectrophotometer (Molecular Devices Inc., CA). For ease of 
comparison between mutants and statistical analyses of independent repetitions, 
activity units were defined as the total activity present in the RgpB+ control mutant 
culture equaling 100 U for culture partitioning studies, the total activity in the 
RgpB+ control mutant cells equaling 100 U for cellular fractionation studies, or the 
total activity in the RgpB+ control mutant membranes equaling 100 U for 
membrane fractionation studies.  
In vivo QC specific inhibition 
Each inhibitor was dissolved in DMSO at 10mM and 100mM concentrations. Five 
ml of a stock culture of P. gingivalis was equilibrated to OD600 = 0.1 in 3 separate 
sealed tubes of 5ml of eTSB media (experiment repeated in triplicate). These tubes 
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are of the correct diameter to be read using the spectrophotometer cuvette reader. 
At inoculation either inhibitor concentration of 100µM or 1mM final concentration 
(DMSO content ≤ 1%) was added or equivalent DMSO ≤ 1% alone. Inoculated 
cultures of P. gingivalis were subsequently placed in an anaerobic chamber. 
Samples consisting of 1.0ml of bacteria were retrieved at 2, 5, and 8 hours post-
inoculation. Samples were then centrifuged, supernatant was decanted, cell 
fraction was washed twice with PBS to remove unbound excess inhibitor. Bacterial 
pellet re-suspended in 300µl PBS and lysed by sonication (3 pulses, 5 s/pulse). 
Eighty µl of lysate used for continuous spectrophotometric assay of glutaminyl 
cyclase as previously described. 
Affinity purified anti-QC Antibodies 
CNBr-activated Sepharose 4B (GE Healthcare Lot # 10039621) was prepared 
according to manufacturer’s specifications. CNBr-activated Sepharose 4B is a pre-
activated resin using the cyanogen bromide method, which couples antibodies or 
other large proteins containing -NH₂ groups to the Sepharose media, without an 
intermediate spacer arm. rPgQC was dissolved in coupling buffer (0.1 M NaHCO3 
containing NaCl 0.5 M) at 5mg/ml of CNBr gel. CNBr beads were washed and 
swelled on a sintered glass filter. rPgQC protein solution mixed with swelled gel 
suspension in an end-over-end mixer for 2 hours at room temperature or overnight 
at 4°C. Remaining active groups were blocked by addition of blocking agent 1.0 
M ethanolamine or 0.2 M glycine at approximately pH 8.0 (2 hours at room 
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temperature or overnight at 4°C). Excess protein was washed away by at least 3 
alternating washes of coupling buffer and acetate buffer (0.1 M pH 4.5 containing 
0.5 M NaCl). Blocking agent was removed with 3-4 washes of coupling buffer 
followed by storage buffer (PBS containing preservative NaN3). Serum passed 
through 0.45µm filter prior to application to the column. Serum was loaded into the 
column, column washed with PBS until A280 reached baseline. The antibody bound 
to the column is eluted with 0.1M Glycine-HCl, pH 2.8. Fractions collected into 
tubes containing 1.0M Tris pH 8.0, to neutralize the eluted antibody. Antibody 
fractions were pooled and dialyze vs. PBS and finally concentrated. ELISA was 
run on serum, flow-thru, and eluate (Fig. 4). 
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Fig 4. Specificity of anti-QC antibodies. A 2-fold serial dilution afterwards was 
continued until no detection using both Western Blot and ELISA, Western blot (left 
panel and Elisa (right panel). ELISA titration was preformed using clear bottom 96-
well plate. Affinity purified QC concentration was determined by BCA assay at 1/10 
dilution to be =8.4mg/ml. Concentration of QC was used @ 0.84mg/ml for first 
dilution (1/512). A 2-fold serial dilution afterwards was continued until absorbance 
was no longer detectable at 450nm wavelength. 
SDS-PAGE and Western Blots 
Samples were analyzed using established protocols ([133]). Samples were first 
boiled in non-reducing SDS-PAGE sample buffer containing 2mM TLCK for 5 min 
to inactivate all gingipains prior to the addition of 1% β-mercaptoethanol and boiled 
for a further 5 min for complete denaturation. Samples were centrifuged briefly at 
13,000 × g, 1 min to remove particulates and the supernatant separated on SDS-
PAGE and gels were stained with Coomassie Brilliant Blue. For Western blot 
analysis resolved proteins were subsequently electrotransferred onto 0.22-μm-
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pore-size nitrocellulose membranes and blocked in 2% BSA/PBS solution 
overnight. RgpB was detected using a 1:2000 dilution of anti-RgpB mouse mAb in 
TTBS (20mM Tris, 500mM NaCl, pH 7.5 supplemented with 0.1% Tween 20) for 
3 h. Membranes were washed four times with TTBS before being probed for 2 h 
with a 1:2000 dilution of an alkaline phosphatase-conjugated rabbit anti-mouse 
polyclonal secondary antibody (Dako Cytomation, Denmark). Development was 
carried out using the AP Conjugate Substrate kit as per manufacturer’s instructions 
(Bio-Rad Lab., CA, USA). The in vivo PgQC and recombinant PgQC was detected 
using a 1:100,000 dilution (1μg ml−1) of affinity purified specific (previously 
described) anti-QC rabbit polyclonal antibody in 5% (w/v) skim milk/TTBS solution. 
Membranes were washed four times with TTBS before being probed for 1 h with a 
1:40,000 dilution of an HRP-conjugated rabbit anti-mouse polyclonal secondary 
antibody (Sigma-Aldrich). Development was carried out using the 
chemiluminescent protocol according to manufacturer’s specification 
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CHAPTER III: RESULTS AND DISCUSSION 
Bacteriodetes SPI substrates typically have a Qln (Q) downstream of the SPI 
cleavage site 
The starting point for this study was the observation that many secreted P. 
gingivalis proteins with a predicted signal peptide also had a glutamine (Q) residue 
immediately downstream. The generality of this observation was confirmed on a 
genome-wide basis using the batch version of SignalP (for gram-negative 
bacteria). These species designations were pooled into “superspecies” groups, 
with particularly well-defined Q-values, and an anomalously large number of 
predicted proteins with predicted signal peptides or type I signal peptides. In none 
of the analyzed species groups, the “superspecies” exceded 15% with exception 
of Cyanobacteria, where 31% species were incompletely designated, often without 
clear signs that several species were pooled (judging from the number of proteins). 
Including the “superspecies”, 337 Bacteroidetes species, 13 Chlorobi species, 59 
Spirochaetes species, 13 Chlamydia species, and 82 Cyanobacteria species were 
analyzed. The number of proteins with predicted signal peptides was above 50 in 
all analyzed species, guaranteeing that incomplete proteomes did not have a major 
influence on Q-values. The medium number of proteins with predicted signal 
peptides was 399 for the Bacteroidetes, 125 for Chlorobi, 163 for Spirochaetes, 
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128 for Chlamydiae, and 195 for Cyanobacteria. Removal of lipoproteins from the 
set of proteins with predicted signal peptides was a relatively “small correction”. 
The median values of the number of proteins with predicted type I signal peptides 
per species were 299 for the Bacteroidetes, 104 for Chlorobi, 146 for Spirochaetes, 
112 for Chlamydiae, and 161 for Cyanobacteria. As lipoproteins have a C after the 
SPII cleavage site, their removal always increased predicted species Q-values. A 
“Q” immediately downstream of the signal peptide was predicted in about half of 
the cases. In the remaining cases, the residue after the signal peptide was 
frequently a cysteine, suggesting that these proteins were lipoproteins/SPII 
substrates. We used LipoP to identify and remove these proteins from the set. In 
the remaining set, which should only contain SPI substrates, the fraction of 
proteins with a Q after the SPI cleavage site exceeded 60%. Additional manual 
checks, including checks with earlier versions of the SignalP program, suggested 
that the true fraction of SPI substrates with a Q directly after the cleavage site may 
be even higher (Fig 5).  
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Fig. 5: Q-Value distribution in Porphyromonas - Fraction of predicated secreted 
proteins with a glutaminyl residue immediately downstream of the SPI cleavage 
site (Q-value) for different Porphyromonas species. Light gray bars indicated 
predictions on SignalP alone, while the dark bars indicate the predictions after 
removal of predicated lipoproteins (identified by LipoP) 
The enrichment of glutamine downstream of the SPI cleavage site did not appear 
to be specific for the proteins of a particular cellular compartment. CELLO [147] 
predictions identified SPI substrate proteins in the inner membrane, the periplasm, 
the outer membrane, and the extracellular space. In all compartments, the fraction 
of SPI substrate proteins with a Q immediately downstream of the SPI site was 
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48% or higher (Table 3), clearly indicating that Q enrichment was not characteristic 
for proteins of a specific compartment. Placement of some SPI client proteins in 
the cytoplasm by the CELLO server suggests that some predictions are in error. 
Even with this reservation, Q enrichment does not appear to be characteristic for 
SPI client proteins in a particular compartment. This conclusion was further 
strengthened by the inspection of protein lists. 
Table 3: CELLO Predictions -  Proteins with or without Q residue in P1’ 
downstream of a type I signal peptide according to their localization, predicted by 
CELLO program. 
Recombinant P. gingivalis PG2157 has QC activity and resides in the inner 
membrane 
The high frequency of newly exposed Q residues in SPI substrates in P. gingivalis 
and the previously reported detection of 7 P. gingivalis proteins with N-terminal 
pyroglutmate [134] suggested that glutamine cyclization might not be 
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spontaneous, but enzymatically catalyzed. A BLASTP query of the P. gingivalis 
proteome with the human QC sequence suggested that PG2157 (also called 
PG_RS09565) may have QC activity. The recombinant protein (without a signal 
peptide) did not exhibit aminopeptidase activity on any of the commercially 
available substrates of general formula NH2-L-Xaa-pNA or NH2-L-Xaa-AMC. 
However, it efficiently converted the fluorogenic substrate L-glutaminyl-AMC into 
its respective pyroglutamic acid derivative (Km = 0.473 mM, kcat = 0.356 s-1, kcat/Km 
= 1.34 mM-1s-1). We therefore refer to PG2157 (PG_RS09565) as PgQC and to 
the recombinant version of the protein as rPgQC. SDS-PAGE of purification of 
rPgQC shown in Fig. 6.  
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Fig. 6: Purification of rPgQC. SDS-Page of different stages of expression and 
purification of recombinant P. gingivalis QC in E. coli BL21. Lane 2: Initial 
bacterial lysate applied to column. Lane 3: Flow through of unbound proteins. 
Lane 4: The fraction of bound recombinant protein plus the binding domain 
containing PSP cleavage sites and HIS-tagged region. Lane 5: Processing of the 
binding domain from the mature protein. Lane 6/7: Separation of the binding 
domain from the rPgQC. Lane 7: Final sample after reapplication on Ni-
Sepharose column to further remove binding domain. Gel electrophoresis was 
completed using 10 µl of respective sample and run according to established 
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Table 4: rPgQC Enzyme Kinetics 
Michaelis/Menton kinetic parameters showing that, indeed, rPgQC is a glutaminyl 
cyclase with much lower affinity for H-Gln-Xaa-Xaa than human or murine QC 
α(Determined in our lab) β([108]) γ([94]) δ([92]) ε([83])  
Sequence analysis of PgQC revealed a canonical signal peptide with the typical 
lipobox (Leu-Ser-Ala-Cys), suggesting that PgQC is a lipoprotein. Lipoproteins are 
translocated across the inner membrane via the Sec system, and initially anchored 
to the inner membrane by covalent attachment of a lipid anchor to the cysteine 
residue, followed by signal peptide cleavage, and typically second N-acetylation. 
Some, but not all lipoproteins are subsequently transferred from the inner to the 
outer membrane. Therefore, we expected that PgQC should be anchored in the 
inner or outer membrane. 
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In order to determine QC localization experimentally, cell extract (CE) of P. 
gingivalis in late exponential/early stationary phase of growth was fractionated into 
cytoplasm and periplasm (CP), total membranes (M), outer membrane (OM), and 
inner membrane (IM). The purity of the membrane fractions was verified by the 
exclusive presence of the biotin-containing 15-kDa biotin carboxyl carrier protein 
(AccA alias MmdC or PG1609) and gingipains in the IM and OM, respectively [136] 
(data not shown).  QC activity of the fractions was then measured using the 
enzyme-coupled assay already used previously to demonstrate the activity of the 
recombinant enzyme. QC activity was found in the IM and in fractions containing 
IM (CE and M) but not CP and OM (Fig. 7A) clearly indicating that PgQC is 
anchored in the inner membrane. This localization was further confirmed by 
Western blot analysis of enriched subcellular fractions using rabbit polyclonal 
antibodies anti PgQC (Fig. 7B).   
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Fig. 7: PgQC is an Inner Membrane Protein.  P. gingivalis in the early phase of 
growth was fractionated into sub-cellular fractions including, whole lysed cell 
extract (CE), cytoplasm (CP), membranes (M), outer membrane (OM), inner 
membrane (IM), and QC activity was measured in each sample results given in 
activity FU/s/µg. The QC activity in each fraction was determined with L-Gln-AMC 
as a substrate using a coupled assay with pyroglutamyl aminopeptidase as an 
auxiliary enzyme. The activity is shown as RF/s. The presence of PgQC antigen in 
fractions was determined by western blot. 
























Porphyromonas gingivalis QC is a zinc metalloenzyme 
Previously, the metal ion content of human QC was unclear. Schilling et 
al. proposed that human QC is a metalloenzyme based on the inhibition by several 
metal ion chelators and the reactivation of apoenzyme by the subsequent addition 
of zinc ions [92]. However, Booth and co-workers reported lower than 0.3 molecule 
zinc ion per hQC molecule which was shown by mass spectrometry [120]. Because 
neither the accessory enzyme for the reaction, pyroglutamyl aminopeptidase, nor 
glutamic acid dehydrogenase, is inhibited by imidazole within the concentration 
range used, both the fluorimetric and spectrophotometric assay were well adapted 
for our purposes. The fluorimetric activity assay data (Table 5) revealed inhibition 
by imidazole. Imidazole completely blocks substrate conversion by binding in the 
active site. Inhibition of the enzyme occurs by removal and chelation of the metal 
ion required for catalytic activity, leaving an inactive apoenzyme. 1,10-
Phenanthroline has been shown to mainly target zinc metallopeptidases and the 
inhibition of QC by 1,10-phenanthroline has been previously described [99]. EDTA 
has been shown under certain conditions to have an activating effect on QC 
catalysis and our data confirms that small amounts display an activating effect. It 
has previously been suggested that inhibition by phenanthroline is not due to metal 
chelation [94]. Also, in addition to being inhibited by 1,10-phenanthroline, P. 
gingivalis QC-catalyzed substrate cyclization was abolished in presence of 
dipicolinic acid, another inhibitor of metalloenzymes. Both chelators inhibited QC 
in a concentration and time-dependent manner, i.e. initial activity that was already 
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inhibited was found to be further reduced after prolonged incubation with the 
compounds (Fig. 8). However, EDTA did not show remarkable inhibition of P. 
gingivalis QC until the concentration was increased almost to 2.0 M P. gingivalis 
QC was almost completely inactivated addition of 5 mM 1,10-phenanthroline. 
Schilling et al. have previously shown that repeated dialysis with chelator-free 
buffer, human QC activity was partially reactivated up to 50–60% but only in the 
presence of EDTA [94].  
Table 5. Attenuation of rPgQC activity by reducing agents and imidazole. 
Reactions were carried out at 30 °C in 0.06 M acetic acid, 0.06 M Mes, and 0.12 
M Tris adjusted to the respective pH by the addition of NaOH or HCl. Data shown 
as residual activity set as 100% for given reaction without inhibitor. Data points are 
averaged triplicates.  
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Fig. 8: Concentration dependent inhibition by 1,10-phenanthroline and EDTA  
Percent residual activity of QC in the presence of either compound was determined 
directly after the addition or pre-incubation of QC with each respective reagent for 
15 min at 30 °C 
To confirm effect of ionic strength on the activity of rPgQC, activity assay buffer 
was supplemented with differing concentrations of NaCl and KCl. rPgQC activity 
saw a sharp drop in activity with the addition of ion salts, but then activity tapered 
off to around 50% activity as the concentration of ion salts increased dramatically. 
(Fig. 9)  
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Fig. 9: Effect of differing concentrations of ionic salts on rPgQC activity. 
Activity using continuous fluorimetric assay displayed as percent activity of QC 
without ionic salts present in the activity assay buffer. 
Sensitivity of the QC reaction to metal ions was also probed. Using the continuous 
fluorimetric assay, a reaction mixture was pre-incubated with the respective ion 
salt. Out of tested divalent cations only Cu2+ exerted strong inhibitory activity 
(Table 6). Other metal ions had only slight effect only at 10 mM concentration in 
the reaction mixture. Interestingly but not surprisingly, increasing Zn2+ 
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concentrations within the QC assays (0.1 mM and higher) considerably reduce QC 
activity, and this has been observed in previous studies [94, 123].  
Table 6: Residual activity of rPgQC in the presence of competing metal ions. 
Given as percent activity of rPgQC standard. Performed on 96-well plate in 
triplicate, experiment repeated in triplicate. Values represent mean of the different 
results.
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Pyroglutamate is present in signal peptidase I substrates 
In order to experimentally demonstrate pyroglutamate at the amino-terminus of 
SPI substrates, previously determined mass spectrometry data was re-analyzed 
for P. gingivalis outer membrane vesicles [73, 136]. Outer membrane vesicles 
(OMVs) are continuously shed. Their vesicle lumen (VL), vesicle membrane (VM) 
and vesicle surface (VS) fractions contain proteins that are derived from the 
periplasm, the outer membrane, and extracellular proteins anchored to the outer 
membrane surface, respectively [148]. Pyroglutamate was inferred from the mass 
of the identified peptide, which is 17 Da less than what the unmodified peptide, 
and also by the fragmentation (MS/MS) pattern of the peptide. The MS/MS spectra 
of these peptides indicate that the -17 Da modification is present near the N-
terminus of each peptide, most consistent with pyroglutamate formation. 
Altogether 27 proteins, all putative SPI substrates, with N-terminal pyroglutamate 
were identified. Interestingly, no semi-tryptic peptides with N-terminal glutamine 
were found in the entire P. gingivalis dataset, suggesting widespread 
pyroglutamate formation, despite the incomplete evidence for the complete set.  
In order to further confirm this conclusion, we compared sequences around the 
cyclization site (and thus the SPI cleavage site) for proteins that were 
experimentally identified, had a glutamine after the predicted SPI cleavage site, 
and for which evidence for pyroglutamate formation was either available or not. 
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The region upstream of the SPI cleavage site, normally not expected to influence 
QC, was included in the comparison in case SPI and QC may act together and QC 
preferences may be influenced by SPI preferences.  However, we did not detect 
clear differences in the sequence logos of the two groups of proteins on either side 
of the critical Q residue, further supporting the conclusion that QC acts broadly and 
is not limited in its activity by specificity for residues adjacent to the substrate 
glutamine residue (Table 7). Also noted is the fact that proteins with experimental 
evidence for pyroglutamate formation at the N-terminus were present in all 
compartments of outer membrane vesicles, this would subsequently stand against 
a role in partitioning proteins between VL, VM or VS of OMVs or the equivalent 
periplasmic space, outer membrane and outer membrane surface that these 
proteins stem from (Table 7). 
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Table 7: Q-value. Proteins from these compartments stem from the periplasm, the 
outer membrane, and the outer membrane surface, respectively. The row “Total” 
indicates the number of localized proteins, the row “Q” the number of proteins with 
a Q exposed by SPI signal peptide cleavage (according to a prior manual 
annotation, not focused on pyroglutamate formation), the row “SIGNALP = Y the 
number of proteins with signal peptide, and the row “SIGNALP = Y&Q” the number 
of such proteins exposing a glutamine after signal peptide cleavage. The row “pGlu 
detected” identifies the number of proteins with experimentally verified 
pyroglutamate. In very few instances, a pyroglutamate was detected in a protein 
not predicted to expose a glutamine after signal peptide cleavage due an 
erroneous SIGNALP prediction. 
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Q downstream of the SPI cleavage site affects RgpA, but not RgpB and Kgp 
secretion 
In order to confirm that pyroglutamate formation does not affect secretion, we 
needed a model system in which pyroglutamate formation does not influence 
protein stability by controlling resilience against aminopeptidases. Gingipains 
RgpA, RgpB and Kgp, the major proteolytic virulence factors of P. gingivalis, are 
good model systems in this respect. The proteins are initially expressed as 
preproproteins, and their type I signal peptides are then cleaved upon import into 
the periplasm, exposing N-terminal glutamine residues. The CTD-domain 
containing proteins are then exported further by the type IX secretion system 
(T9SS). Upon secretion from the periplasm to the outer membrane surface, the 
pro-regions are rapidly degraded, leaving only the mature forms that no longer 
contain the expected pyroglutamate N-terminal residue. This is an asset for 
comparing protein activity independent of issues of protein stability, but it 
unfortunately also prevents detection of the pyroglutamylation of the pro-region in 
wild-type P. gingivalis strains. Nevertheless, we expect pyroglutamate formation 
based on its widespread occurrence (see above), and also because proRgpB is 
blocked for Edman degradation in a type IX secretion (T9SS) mutant that retains 
non-degraded proRgpB in the periplasm.  
We used homologous recombination to construct P. gingivalis W83 strains 
expressing RgpAQ24N, RgpBQ25N, RgpBQ25A and KgpQ20N, in ΔRgpB, 
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ΔRgpA and wild-type backgrounds, respectively. Due to overlapping RgpA and 
RgpB specificities (both enzymes cleave after arginine residues), RgpA activities 
had to be compared in ΔRgpB background, and vice versa, whereas Kgp activities 
could be compared in a wild-type background. Mutation of the RgpA, RgpB or Kgp 
glutamine after the SPI cleavage site did not alter P. gingivalis growth or the 
extracellular activity of prolyl tripeptidyl peptidase secreted by P. gingivalis 
independent of T9SS. Gingipain activity was assayed in full cultures and the cell-
free culture medium from cultures grown to the mid-exponential (OD600 nm = 0.6-
0.8), late exponential/early stationary (OD600 nm = 1.2-1.4) and stationary (OD600 nm 
>2.0) phase of growth. We assayed either total extracellular activity, or separately 
the activities associated with the outer membrane surface and with the culture 
medium. In all cases, activities increased strongly over time from mid-exponential 
to late stationary cultures. Mutation of the Q after the SPI cleavage site however, 
had surprisingly variable effects on the different gingipains.  
The Q24N mutation in RgpA reduced overall activity several-fold, whereas the 
equivalent substitution Q25N (and also Q25A) in RgpB and Q20N in Kgp lacked 
significant effect, irrespective of whether cells were assayed in mid-exponential, 
late exponential/early stationary or late stationary phase (Fig. 10). 
For all three gingipains, most of the activity was cell-associated, with only a minor 
contribution from protein in the medium. For RgpA, the Q24N decreased cell 
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Fig. 10:  Q downstream of the SPI affects RgpA not RgpB or Kgp. 
Porphyromonas gingivalis strains were grown in at least six independent cultures 
to mid-exponential (OD600 in the range 0.6–0.8), late exponential/early stationary 
(OD600 in the range 1.4–1.6) and late stationary phase (OD600 > 2) of growth 
then adjusted to the same OD600 of 0.6, 1.4, and 2, respectively. Gingipain activity 
was measured in whole cultures with appropriate substrates. One-way ANOVA 
tests were carried out separately for the three gingipains (degrees of freedom 
RgpA: 5,30; RgpB: 8,45; Kgp: 5,48). Significance was judged applying the 
Bonferroni correction for multiple hypotheses (conservatively assuming all against 
all comparisons, even though only comparisons between wild-types and mutants 
are of interest) for a p = 0.05 threshold. The ¨¨¨ symbol indicates p < 0.001, the 
¨¨¨¨ symbol p < 0.0001. 
associated activity several fold, in all phases of growth. Activity in the medium was 
also significantly reduced in late stationary phase, the only growth stage with more 
than a marginal contribution from protein in the medium to the overall activity. In 
contrast, for RgpB, both the Q25N (and also Q25A) mutations altered the activity 
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associated with cells and in the medium at most insignificantly. There was also no 
redistribution of activity between cells and medium. For Kgp, the Q20N substitution 
had an unexpected effect. Although the overall activity was not significantly altered, 
Q substitution in Kgp increased activity in the medium at the expense of activity 
associated with cells, especially in mid-exponential phase, and to a lesser extent 
also in late exponential/early stationary phase. 
We suspect that the diverse effects of Q substitution must be related to 
complicated posttranslational processing of Kgp and RgpA leading to an assembly 
of large multidomain complexes of the catalytic and hemagglutinin-adhesion 
domains derived from initial polyproteins anchored into the OM via A-LPS [149] 
rather than per se translocation of the OM.  
QC is Essential for P. gingivalis Survival 
Creation of non-polar QC knock-out strains in P. gingivalis was an untenable goal 
due to apparent lethality of absence of QC activity. P. gingivalis QC (PG_2157) 
lies within an operon containing genes PG_2157, PG_2156, and a HemG 
(PG_2158), and in initial attempts downstream effects were present in the gene 
replacement (Fig. 11). t. Subsequently we attempted construction of non-polar 
knock out strains, without disrupting the operon but it was evident that gene 
PG1885 is essential for survival of P. gingivalis bacteria. Partial success was 
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achieved with only one survivable mutant in which erythromycin was successfully 
inserted between PG_2157 and PG_2158. 
Fig. 11: Structural Schematic of the P. gingivalis operon containing QC. Gene 
coding sequence PG_2157 (QYT). PgQC lies just prior to PG_2156 and PG_2158 
and non-polar disruption of PG_2157 was lethal. 
Following these revelations, we shifted focus into examining and manipulating the 
possible QC targets that were identified during the SignalP QC distribution data.  
P. gingivalis growth attenuation by PgQC Inhibition 
After assessing the effects of non-specific inhibitors of QC activity both in vitro and 
in vivo, specific inhibitors were produced to experimentally determine the effects 
of reduced PgQC activity on bacterial growth. With the assistance and cooperation 
of Probiodrug in Germany, banks of specific inhibitors were screened against 
purified rPgQC. Promising candidates were then analyzed for inhibition on QC 
PG_2156 PG_2157 PG_2158
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activity. The initial inhibitor was LL29. Inhibitor LL29 was dissolved in DMSO into 
100mM concentration and incubated with fresh P. gingivalis liquid culture. 1.5ml of 
liquid culture of P. gingivalis were lysed, and remaining LL29 inhibitor was washed 
with PBS and QC activity was recorded using fluorimetric assay. In these cell 
lysates cultures that were administered 100mM LL29 showed a time-dependent 
competitive inhibition of PgQC. In addition to the in vitro effects of LL29 on PgQC, 
corresponding 1.5 mL cultures of early-log phase P. gingivalis were incubated 
overnight to examine the inhibitors’ effect on P. gingivalis growth. After 24-hour 
incubation in anaerobic chamber, the OD600 of cultures was analyzed. LL29 
inhibitor incubated cultures showed a decrease in absorbance equivalent to 33% 
cell density decrease. Initially we suspected that the cell permeability may be a 
complicating factor or extracellular inhibitor could be degraded by cell factors. To 
effectively rule out inhibitor penetration into bacteria cells, these experiments were 
repeated in triplicates but concentrations of LL29 were increased 10 fold to 1mM 
and compared to initial 100mM concentration. (Fig. 12)  
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Fig. 12: LL29 Inhibits P. gingivalis growth. 5 ml of a stock colony of P. gingivalis 
equilibrated to OD600 = 0.1 in 3 separate sealed tubes of 5 ml of eTSB media in 
triplicate. At inoculation 1mM inhibitor 084 final concentration (DMSO ≤ 1%) was 
added or equivalent DMSO ≤ 1% alone was added. Inoculated colonies of P. 
gingivalis were subsequently placed in an anaerobic chamber. Statistical difference 
(p<0.0001) shown between DMSO and 1mM LL29 are demonstrated with ****. 
What is striking is the group with 1mM LL29 showed a remarkable decrease in QC 
activity along with a 50% decrease in total liquid culture density (Fig 12). 24-hour 
growth curves were plotted to demonstrate LL29’s effect over time (Fig. 12B). 
Absorbance reading were taken at 1-hour intervals over a 28-hour period and 
plotted to display accurate growth curves. These showed that the cultures with 
1mM LL29 only reached an absorbance of less than half of the control group 
(DMSO alone). RgpA-null strain cultures were pre-incubated with LL29, pelleted, 
washed three times with PBS and then resuspended in fresh eTSB media to 





























removed trace amounts of excess LL29 not taken up by the bacteria. This 
eliminated excess inhibitor from the reaction. 100mM LL29 demonstrated time-
dependent inhibiton of W83 in vivo QC activity. This inhibition was more 
pronounced at 1mM concentration (Fig. 13).  
Fig. 13: PgQC in vivo inhibition by LL29. Analysis of QC activity in vivo W83 P. 
gingivalis. LL29 had a time-dependent inhibitory effect on QC activity at final 
concentration 100mM. Whole cell activity was measured after cell lysis. Statistical 
difference (p<0.0001) shown between DMSO and 1mM LL29 are demonstrated 
with ****. 
Samples were then taken at 2, 5, and 8-hour marks and whole cell gingipain activity 
assays were completed. Using the data stated above, further screening of potential 
specific inhibitor produced 5 additional possible candidates. Inhibitors: 019, 071, 
073, 101, and 084 were roughly screened using in vitro PgQC assays. Each 
inhibitor showed significant attenuation of PgQC activity but only 084 completely 
obliterated QC activity (Fig. 14). Previously, each respective inhibitor was 
incubated within the reaction mixture prior to initiation of the assay. In the case of 
















































084, we wanted to determine if the inhibitor had a bacteriocidal or bacteriostatic 
effect, so the growth curve was repeated with addition of 1mM 084 at mid-
logarithmic bacterial growth (Fig. 14F) After addition of 084, bacterial cell density 
decreased slowly up to 24 hrs after which it remained static. This suggests some 
mixed bacteriostatic/bacteriocidal killing of P. gingivalis after addition of inhibitor 
084 at 1mM final concentration.  
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Fig. 14: 24-hour growth Inhibition of P. gingivalis W83. 5 ml of a stock colony 
of P. gingivalis equilibrated to OD600 = 0.1 in 3 separate sealed tubes of 5 ml of 
eTSB media in triplicate. At inoculation 1mM inhibitor 084 final concentration 
(DMSO ≤ 1%) was added or equivalent DMSO ≤ 1% alone was added. 
Inoculated colonies of P. gingivalis were subsequently placed in an anaerobic 
chamber. Absorbance was measure at each hour for 24 hours. Inhibitor 084 had 

















































































High Q-values are typical for Bacteroidetes species, but not related phyla 
In the following, we call the fraction of signal peptidase I substrates that have a 
glutamine immediately downstream of the SPI cleavage site the Q-value. The high 
Q-value is not unique for P. gingivalis but is shared with other bacterial species. 
LipoP corrected SignalP predictions for various Porphyromonas species suggest 
Q-values between 59% (for P. somerae) and 77% (for P. macacae). Manual 
inspection of automatic prediction suggested that even the high Q enrichment 
values are still underestimated due to the mis-prediction of some signal peptide 
cleavage sites. 
Porphyromonas species belong to Bacteroidetes, which in turn are placed in the 
FCB superphylum containing the Fibrobacteres, Chlorobi, and Bacteroidetes. In 
the Bacteroidetes group, 332 of 334 species (i.e. > 99%) had predicted Q-values 
above 48%. Averaged across species, the Q-value was 71%, with a standard 
deviation for the variation between species of around 10% percent (outliers 
included). The two low Q-value outlier species (Bacteroides pectinophilus, 4% and 
Candidatus cloacimonas 24%) had a suspiciously low number of predicted 
proteins with signal peptides (21 and 83, compared to typically 300 in this group), 
suggesting a possible problem with sequencing or annotation rather than a 
genuine difference. CELLO predictions for T. forsythia confirm the conclusion for 
P. ginigivalis that the enrichment of glutamine residues directly after the SPI 
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cleavage site is not specific for proteins of a particular cellular compartment (Table 
3). Across the entire FCB superphylum, Q-values were not consistently high. For 
most sequenced Chlorobi species, the predicted Q-value was below 9%. Three 
outliers were found in this group in little characterized bacteria (annotated as 
Chloroherpeton thalassium, Q-value 55%, Chlorobi bacterium, Q-value 63% and 
Chlorobium sp., Q-value 67%). Outside the Bacteroidetes and Chlorobi, a 
continuum of Q-values was found, ranging from 2% (Chlorobaculum parvum) to 
77% (Ignavibacterium album), with no obvious pattern. 
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Fig. 15: Q-values averages and Q-value distributions for different groups of 
bacteria. The Q-value was determined separately for every species in the groups. 
(A) Average Q-values for the species groups (species are given equal weight in 
the average), and the standard deviation of Q-values. Bacteroidetes have 
significantly higher Q-values than Chlorobi, Spirochoaetes, Chlamydiae, or 
cyanobacteria (p < 1E-6 for comparisons of Bacteroidetes against any of the other 
species groups according to the Wilcoxon rank sum test). (B) Cumulative Q-value 
distributions. For identification of species groups, refer to the symbols in the right 
panel (near Q-value 1). The Q-values for Bacteroidetes species are higher than 
for the other species groups also judging from cumulative distributions (p < 1E-6 
according to the Kolmogorov–Smirnov test). Species were classified as having an 
animal- or plant-type QC according to BLASTP searches using the human and A. 
thaliana QC. 
We also determined the cumulative Q-value distribution for selected bacterial phyla 
(Fig. 15), thought to be relatively closely related to Bacteroidetes [150]. Predicted 
Q-values for Chlamydiae and Spirochaetes species were typically below 20% and 
thus much lower than in Bacteroidetes. Cyanobacterial species typically also had 
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lower Q-values. However, in a small fraction of cyanobacterial species (~5%), Q-
values were not much lower than those of Bacteroidetes. High Q-values were for 
example found for Scytonema millei (40%), Leptolyngbya valderiana (45%), 
Hassallia byssoidea (61%), and Aphanocapsa montana (67%) (Fig 15).  
Bacteroidetes have orthologues of animal and plant QCs 
We searched complete bacterial proteomes in UNIPROT for orthologues of 
animal- and plant-type QCs. In a first step, we used the prototypical human and A. 
thaliana QC sequences as queries. In a set of 1878 proteomes, we found 602 
animal-type QCs, among them 402 (67%) in Bacteroidetes. We also identified 991 
plant-type QCs, among them 401 (40%) in Bacteroidetes. As Bacteroidetes 
account for less than 10% of the proteome data (and even less in the redundant 
set), it is clear that QCs, particularly of the animal-type, are enriched in the 
Bacteroidetes. Orthologues of animal- and plant-type QCs tended to segregate 
according to phylogeny. Animal-type QCs were typically found in Bacteroidia, 
plant-type QCs in Flavobacteriia. As the number of candidate QCs was smaller 
than the number of proteomes, we attempted to enlarge the set of candidate QCs 
by carrying out BLASTP queries with representative sequences from Bacteroidia 
and Flavobacteriia, the two largest groups within the Bacteroidetes.  Starting from 
these sequences, and correcting for species duplicates, we identified 574 
Bacteroidetes species containing animal-type and 507 Bacteroidetes species 
containing plant-type QC enzymes, but only 63 species containing both types of 
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enzymes (E-value threshold 1E-4), compared to 1540 species in the duplication 
corrected proteome dataset.  
We also attempted iterated searches, using representatives of CD-HIT identified 
sequence clusters [151] to initiate additional searches. With this procedure, still 
more putative QCs were identified, but the concentration of hits in the 
Bacteroidetes phylum was reduced, likely because the set of putative QCs became 
contaminated by peptidases. Despite this complication, we can conclude from the 
simpler BLASTP searches that most and perhaps even all Bacteroidetes species 
have enzymes that could be suitable for glutamine cyclization. In the following, we 
focus on the candidate QC enzymes that can be demonstrated in a single BLASTP 
step with tight E-value threshold to be orthologous to the prototypical animal- or 
plant QC enzymes. 
The orthologues of animal and plant-like QCs in Bacteroidetes have intact 
active sites  
In order to assess the chances that the animal- and plant-type QCs in bacteria 
were active, we checked alignments for the presence of key active site residues. 
The prototypical animal QC is the human enzyme, hsQC. Its active site is built from 
E201 (involved in proton shuttling), D159, E202 (involved in binding the active site 
Zn2+ ion), and D248 (involved in both). In the Bacteroidetes orthologues of human 
QC, D159, E201 and D248 are highly conserved (>98%). In contrast, E202 is 
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conserved only in 9% of Bacteroidetes orthologues, and replaced by an aspartate 
residue almost all remaining cases (exceptions <1%). As aspartate and glutamate 
can both serve as Zn2+ ligands, we suspect that this substitution may not 
compromise activity, or may even be required to accommodate slight changes in 
the overall protein structure compared to HsQC. This conclusion is supported by 
the observation that an aspartate is also present in the 202 position in the PgQC 
enzyme, which we have already shown to be an active QC enzyme. 
The prototypical plant QC is the enzyme from C. papaya, CpQC. Its active site is 
not as well understood as the active site of hsQC, but it is thought that E69, N155 
(probably involved in proton shuttling) and N155, K225 and Q24 (probably involved 
in stabilizing the oxyanion intermediate) play a role in catalysis. Among the 
Bacteroidetes orthologues, E69, N155 and K225 are strictly conserved. In contrast, 
Q24 was conserved only in 81% of cases, and replaced by a glutamate in the 
remaining cases. The same substitution occurs in many plant enzymes, and also 
in the experimentally studied bacterial Xanthomonas campestris QC (XcQC). In 
this special case, the (natural) glutamate variant is still active, albeit an order of 
magnitude less so than the engineered glutamine variant [91], suggesting that both 
glutamine and glutamate in the active site are compatible with activity, although 
not necessarily at the same level.   
We conclude from this analysis that Bacteroidetes orthologues of animal and plant 
QCs are likely to be active enzymes. This is directly suggestive of QC activity plant 
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QC orthologues, and compatible with either QC or aminopeptidase activity for 
animal QC orthologues. Classification of the enzymes as lipoproteins (like PgQC) 
could strengthen the case for QC activity.  
Most Bacteroidetes orthologues of animal and plant QCs are predicted 
lipoproteins 
Among 401 orthologues of human QC in Bacteroidetes, 323 (~80%) were 
predicted lipoproteins, 59 (~15%) were predicted SPI substrates (~15%), and the 
remaining 19 (~5%) were predicted to be cytoplasmic. As orthologues of human 
QC are highly enriched in Bacteroidetes, relatively few were found in species not 
belonging to the Bacteroidetes. Among these, the fraction of predicted lipoproteins 
was much smaller. Only 38 (~34%) enzymes were predicted to be lipoproteins, 40 
(~36%) were classified as SPI substrates, and remaining 34 (~30%) as cytosolic 
proteins.   
Among 430 orthologues of A. thaliana QC in Bacteroidetes, 376 were (~87%) 
computationally classified as lipoproteins, 20 (~5%) as SPI substrates, and 34 
(~8%) as cytoplasmic proteins. The predominance of predicted lipoproteins among 
plant-type QCs was much less pronounced when bacterial homologues of plant 
QC in general were considered. Among the 1000 bacterial proteins most similar to 
A. thaliana QC, predictions classified 475 (~48%) as lipoproteins, 338 (34%) as 
SPI substrates, and 175 (18%) as cytosolic proteins.  
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Sensitivity (true positive rate, recall) of the LipoP algorithm for gram-negative 
bacteria has been reported to be around 90% [140]. The fraction of bacterial QCs 
predicted to be lipoproteins in non-Bacteroidetes species is much smaller, 
suggesting that not all are lipoproteins. In Bacteroidetes, the fraction of QC 
proteins predicted as lipoproteins comes close to the predicted sensitivity of the 
prediction algorithm. Thus, it appears likely that most if not all QCs in Bacteroidetes 
are lipoproteins, like the prototypical PgQC from P. gingivalis. 
Proteomic datasets confirm glutamine cyclization in several Bacteroidetes 
species 
In order to confirm widespread pyroglutamyl formation in Bacteroidetes, and not 
only P. gingivalis, we analyzed additional data from previously reported proteomic 
studies [73, 134-137]. In addition to the already discussed 27 proteins from P. 
gingivalis, the collated data identify 27 proteins in Tannerella forsythia, 13 in 
Parabacteroides distasonis, 8 in Prevotella intermedia and 7 in Cytophaga 
hutchinsonii with N-terminal pyroglutamate residue. N-terminal residues other than 
pyroglutamate were rare, as predicted from the bioinformatic studies.  
Pyroglutamate was not detected at the amino-terminus of all SPI substrates that 
are predicted to expose an N-terminal glutamine residue after SPI cleavage, most 
likely due to incomplete coverage and not due to selective pyroglutamate 
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formation. As already reported for the P. gingivalis proteins, semi-tryptic peptides 
were never found to start with glutamine, even though internal tryptic peptides 
could be identified with N-terminal glutamine in both modified and unmodified 
states. Other circumstantial evidence also supports widespread rather than 
selective glutamine cyclization. We focused in particular on the T. forsythia data, 
which contained pyroglutamate evidence for the largest number of proteins in one 
species. Experimentally detected proteins (by any peptide, not necessarily a 
semitryptic peptide) with glutamine after the SPI site were partitioned into proteins 
with and without evidence for glutamine cyclization (Figure 16). As already 
reported for P. gingivalis, amino acids around the Q were similar in the two groups, 
supporting broad QC specificity. 
Fig. 16: Sequence downstream of Q in T. forsythia SPI proteins. Comparison 
of sequence logos around Q downstream of the signal peptide for T. forsythia SPI 
proteins. Top – experimentally demonstrated or  Bottom – undetermined Q 
cyclization in OMVs. The signal peptidase motif A-X-A upstream of the SPI 
cleavage sites is marked by the arrow. Only proteins with a Q after the predicated 
SPI site have been included in the comparison panel in the bottom.  
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In addition, QC activity was detectable in T. forsythia using the previous method 
for continuous flourimetric QC activity in P. gingivalis (Fig 17).  
Fig. 17: QC activity in T. forsythia. T. forsythia in the early phase of growth was 
measured using whole cell extract, and QC activity was measured in each sample 
results given in activity FU/s/µg. QC activity was determined in each fraction 
standardized to the volume of washed cells were suspended for sonication. The 
QC activity was determined with L-Gln-AMC as a substrate using a coupled assay 
with pyroglutamyl aminopeptidase as an auxiliary enzyme. P. gingivalis W83 strain 
used here for comparison.  
Following this experimentally measured QC activity of a Bacteriodes sp. Other than 
P. gingivalis, we decided to test the specificity of LL29 against the T. forsythia QC. 






















forsythia (Fig 18). This could be easily explained by substrate preference or 
variability in the active site structural motifs.  
Fig. 18: LL29 Does not inhibit TfQC. T. forsythia in the early phase of growth 
was measured using whole cell extract, and QC activity was measured in each 
sample results given in activity FU/s/µg. QC activity was determined in each 
fraction standardized to the volume of washed cells were suspended for 
sonication. The QC activity was determined with L-Gln-AMC as a substrate using 
a coupled assay with pyroglutamyl aminopeptidase as an auxiliary enzyme. P. 
gingivalis W83 strain used here for comparison. Statistical difference according to 
one-way ANOVA (p<0.0001) shown between DMSO and 1mM LL29 are 
demonstrated with ****. 
Pyroglutamate detection is not consistent for paralogue families in a single 






















not predictive for the orthologue in another species. In a first step, we used 
BLASTP (E-value threshold 10-9) to identify orthologous proteins in T. forsythia and 
P. gingivalis with experimentally verified localization. Only unique pairs were used, 
and proteins with more than one paralogue in either species were excluded. 
Among the 41 pairs, 9 and 3 were found to have a pyroglutamate at the N-terminal 
end. Based on a random association alone, one would then expect experimental 
pyroglutamate demonstration for both proteins of a pair in (9*3)/41 ~ 0.7 cases. In 
fact, one such case was observed.  
Together, the above observations are consistent with general glutamine 
cyclization, partially masked by incomplete mass spectrometry coverage (for 
example, due to low expression of some proteins, or because semi-tryptic peptides 
are too short or too long for efficient mass spectrometry detection). As already 
seen for P. gingivalis, pyroglutamate formation was not characteristic for proteins 
of a particular compartment, as T. forsythia proteins with pyroglutamate were also 
found in the vesicle lumen, in vesicle membranes, and on the vesicle surface of 
OMVs, which represent periplasmic, integral OM and cell-surface associated 
proteins, respectively. 
A model for pyroglutamate formation in proteins destined to the periplasm, 
the outer membrane, the outer membrane surface, or the medium 
Together, this body of data suggest a model for Bacteridetes SPI substrates that 
reside in or transit through the periplasm. Their signal peptides are cleaved by SPI, 
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a lipoprotein with active site on the periplasmic face of the inner membrane. 
Because of the enrichment of glutamine immediately downstream of the SPI 
cleavage site, this reaction typically exposes an amino-terminal glutamine residue. 
QC, another lipoprotein, also with active site on the periplasmic face of the inner 
membrane, is then ideally positioned to catalyze the cyclization of the glutamine 
residue to a pyroglutamate residue. The cooperation between SPI and QC is 
apparently efficient, suggesting either direct interaction or joint anchoring in lipid 
domains, which we have not yet tested. Pyroglutamate formation occurs for 
proteins that remain in the periplasm, as well as for proteins that are transported 
further into or through the outer membrane. We suggest the term “Q-rule” to 
describe the finding that glutamines are enriched after SPI cleavage sites, and that 
these glutamine residues are cyclized to form N-terminal pyroglutamate residues 
in proteins that are destined to the periplasm or beyond (Fig. 19). 
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Fig. 19: Hypothesized Pathway for Pyroglutamate formation by QC. 
Schematic representation of the pathway for pyroglutamate formation at the amino 
terminus of proteins that transit to or through the periplasm. It is currently unclear 
whether or not SPI and QC are physically associated. Pyroglumate formation has 
not yet been tested for proteins of the inner membrane. 
Importance of the Q-rule pathway 
The Q-rule pathway seems to be biologically important, not only judging by the 
number of proteins that are subject to the rule. P. gingivalis glutaminyl cyclase is 
present in both virulent and avirulent strains [152]. According to an unbiased large 
scale transposon mutagenesis screen [153], the enzyme is essential even in 
laboratory culture conditions when P. gingivalis is not pitted against a host immune 
system. It is currently unclear why the enzyme is essential. Our data speak against 
a role of the modification in protein sorting. Given the host-associated lifestyle of 
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many Bacteroidetes species, it is possible that glutaminyl cyclization protects 
secreted proteins against host aminopeptidases (excluding of course the host 
pyroglutamate aminopeptidases). However, this model does not explain why the 
Q-rule applies to SPI substrates that remain in the periplasm or why the glutaminyl 
cyclase is essential for P. gingivalis in culture conditions, unless P. gingivalis has 
become unable to do without the Q-rule and now needs pyroglutamate formation 
for protection against its own periplasmic proteases as well. Further lending 
credence to this theory is the lethality of QC knock-outs. 
Future topics 
One of the lingering questions remaining is how the QC and SPI interact withing 
the periplasmic space. It was not evaluated whether these are or are not in intimate 
contact or physically linked to one another, although their function is clearly linked. 
Another point of interest is perhaps although only downstream effects of gingipain 
secretion were evaluated in this project, P. gingivalis is fully capable of surviving 
without gingipain activity. Perhaps another essential protein or proteins processed 
through this system is blocked, thereby leading to cell death. Either way this 
system poses as a possible target for future studies and continued research.  
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